Gilead to appeal Indian Tamiflu decision
This article was originally published in Scrip
Executive Summary
Gilead Sciences, whose patent application for the antiviral Tamiflu (oseltamivir) was rejected in India, is expected to appeal against the decision. Gilead said that it expects to vigorously defend its patent and the scientific innovation on which it's based, according to a report in the local media. Gilead's application has been opposed by Cipla and another domestic firm, Intermed (scripnews.com, April 23rd, 2009).